Quantum Biopharma (NASDAQ:QNTM) & Tharimmune (NASDAQ:THAR) Head to Head Contrast

Tharimmune (NASDAQ:THAR) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Risk and Volatility

Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.

Valuation & Earnings

This table compares Tharimmune and Quantum Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20 million	($3.99)	-0.82
Quantum Biopharma	N/A	N/A	-$26.17 million	($8.72)	-0.46

Tharimmune is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tharimmune and Quantum Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Quantum Biopharma	N/A	-436.23%	-150.85%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Tharimmune and Quantum Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1	0	0	0	1.00
Quantum Biopharma	1	0	0	0	1.00

Institutional and Insider Ownership

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 6.7% of Tharimmune shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Quantum Biopharma beats Tharimmune on 5 of the 8 factors compared between the two stocks.

About Tharimmune

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.